Payment overview · 2025
General Payments
$1,170.98
64 reported records · 17 companies
Healthcare provider profile · identity verified
George Vanweelden, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WINTERSVILLE, OH · NPI 1336146521
Verified facts
What the public records show
CMS Open Payments records show George Vanweelden, DO received $1,170.98 in general payments during 2025 across 64 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Edarbi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $188.93 | 16.1% | 8 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $140.95 | 12.0% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $134.81 | 11.5% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $113.27 | 9.7% | 5 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $105.34 | 9.0% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.67 | 7.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.15 | 5.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.48 | 5.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.76 | 5.3% | 3 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $40.72 | 3.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.18 | 2.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $28.94 | 2.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.93 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.50 | 2.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.81 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.23 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.31 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,170.98 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $140.95 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $126.79 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $113.27 | 5 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $105.34 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.02 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $88.01 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $87.67 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $87.22 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.48 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.68 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $41.90 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.73 | 2 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.93 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
81 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1002 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 663 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 622 | 156 |
| Escitalopram Oxalate | Escitalopram Oxalate | 485 | 108 |
| Omeprazole | Omeprazole | 481 | 107 |
| Metformin Hcl | Metformin Hcl | 473 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 466 | 108 |
| Lisinopril | Lisinopril | 429 | 100 |
| Simvastatin | Simvastatin | 375 | 84 |
| Amoxicillin | Amoxicillin | 255 | 171 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 238 | 53 |
| Atenolol | Atenolol | 229 | 58 |
| Sertraline Hcl | Sertraline Hcl | 217 | 46 |
| Losartan Potassium | Losartan Potassium | 215 | 58 |
| Glimepiride | Glimepiride | 214 | 51 |
| Trazodone Hcl | Trazodone Hcl | 208 | 36 |
| Azithromycin | Azithromycin | 175 | 127 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 172 | 130 |
| Gabapentin | Gabapentin | 169 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 38 |
| Valsartan | Valsartan | 163 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 34 |
| Furosemide | Furosemide | 144 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 36 |
| Potassium Chloride | Potassium Chloride | 141 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 33 |
| Clonidine Hcl | Clonidine Hcl | 126 | 32 |
| Carvedilol | Carvedilol | 122 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 110 | 29 |
| Allopurinol | Allopurinol | 102 | 28 |
| Alendronate Sodium | Alendronate Sodium | 100 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 99 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 18 |
| Montelukast Sodium | Montelukast Sodium | 87 | 22 |
| Lovastatin | Lovastatin | 85 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 22 |
| Synthroid | Levothyroxine Sodium | 81 | 20 |
| Famotidine | Famotidine | 80 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 19 |
| Eliquis | Apixaban | 78 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 13 |
| Meloxicam | Meloxicam | 76 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 70 | 52 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 64 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 62 | suppressed |
| Alprazolam | Alprazolam | 58 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 13 |
| Clarithromycin | Clarithromycin | 55 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | suppressed |
| Fluconazole | Fluconazole | 54 | 26 |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Nystatin | Nystatin | 52 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | 13 |
| Cefuroxime | Cefuroxime Axetil | 50 | 44 |
| Methylprednisolone | Methylprednisolone | 48 | 39 |
| Cephalexin | Cephalexin | 46 | 36 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 37 |
| Ibuprofen | Ibuprofen | 40 | 21 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 12 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 19 |
| Valacyclovir | Valacyclovir Hcl | 30 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 18 |
| Glipizide | Glipizide | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Edarbi | Azilsartan Medoxomil | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Glyburide | Glyburide | 22 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Etodolac | Etodolac | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Np Thyroid | Thyroid,pork | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 14 | 14 |
| Latanoprost | Latanoprost | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,170.98 · 64 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, DAYBUE, Dexcom G6 Transmitter, EDARBI, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, INCEPTIV, JARDIANCE, Kerendia, MOUNJARO, NP Thyroid 60, NURTEC ODT, OTEZLA, PAXLOVID, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, ZAVZPRET, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error